BR112014004879A2 - uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas - Google Patents

uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas

Info

Publication number
BR112014004879A2
BR112014004879A2 BR112014004879A BR112014004879A BR112014004879A2 BR 112014004879 A2 BR112014004879 A2 BR 112014004879A2 BR 112014004879 A BR112014004879 A BR 112014004879A BR 112014004879 A BR112014004879 A BR 112014004879A BR 112014004879 A2 BR112014004879 A2 BR 112014004879A2
Authority
BR
Brazil
Prior art keywords
aromatase inhibitor
related diseases
hypogonadism
relates
treatment
Prior art date
Application number
BR112014004879A
Other languages
English (en)
Other versions
BR112014004879B1 (pt
Inventor
Taylor Ann
B Klickstein Lloyd
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014004879(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014004879A2 publication Critical patent/BR112014004879A2/pt
Publication of BR112014004879B1 publication Critical patent/BR112014004879B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

resumo patente de invenção: "uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas". a presente invenção refere-se a um método de aumento de níveis de testosterona e tratamento de hipogonadismo e doenças relacionadas com o inibidor de aromatase 4,4'-[fluor-(1-h-1,2,4-triazol-1-il)metileno]bisbenzonitrila. a presente invenção também se refere a um método de aumento de níveis de testosterona e tratamento de hipogonadismo e doenças relacionadas com o inibidor de aromatase 4,4'-[fluor-(1-h-1,2,4-triazol-1-il)metileno]bisbenzonitrila em um regime de dosagem particular. a invenção também se refere às composições farmacêuticas compreendedo o referido inibidor de aromatase 4,4'-[fluor-(1-h-1,2,4-triazol-1-il)metileno]bisbenzonitrila, opcionalmente em combinação com outros ingredientes ativos. além disso, a presente invenção refere-se a kits compreendendo as referidas composições farmacêuticas juntamente com instruções de como administrá-las.
BR112014004879A 2011-09-08 2012-09-06 uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas, composição farmacêutica oral, e kit BR112014004879B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US201261638588P 2012-04-26 2012-04-26
PCT/US2012/053844 WO2013036562A1 (en) 2011-09-08 2012-09-06 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Publications (2)

Publication Number Publication Date
BR112014004879A2 true BR112014004879A2 (pt) 2017-03-14
BR112014004879B1 BR112014004879B1 (pt) 2020-01-28

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014005434-7A BR112014005434B1 (pt) 2011-09-08 2012-09-06 Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação
BR112014004879A BR112014004879B1 (pt) 2011-09-08 2012-09-06 uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas, composição farmacêutica oral, e kit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112014005434-7A BR112014005434B1 (pt) 2011-09-08 2012-09-06 Composições farmacêuticas compreendendo inibidor da aromatase 4,4'-[fluoro-(1h-1,2,4triazol-1-il)metilemo]bisbenzonitrila e seu método de preparação

Country Status (30)

Country Link
US (4) US9370505B2 (pt)
EP (2) EP2753312B1 (pt)
JP (2) JP6051467B2 (pt)
KR (3) KR101872561B1 (pt)
CN (2) CN103781476B (pt)
AR (1) AR087790A1 (pt)
AU (2) AU2012304693B2 (pt)
BR (2) BR112014005434B1 (pt)
CA (2) CA2845929C (pt)
CL (1) CL2014000552A1 (pt)
CY (2) CY1118461T1 (pt)
DK (2) DK2753313T3 (pt)
ES (2) ES2613667T3 (pt)
HR (2) HRP20170003T1 (pt)
HU (2) HUE031435T2 (pt)
IL (1) IL231234A (pt)
IN (1) IN2014DN01619A (pt)
LT (2) LT2753313T (pt)
MX (2) MX360315B (pt)
PE (1) PE20141584A1 (pt)
PL (2) PL2753312T3 (pt)
PT (2) PT2753313T (pt)
RU (2) RU2617510C2 (pt)
SG (2) SG2014012132A (pt)
SI (2) SI2753313T1 (pt)
TN (1) TN2014000059A1 (pt)
TW (1) TW201316987A (pt)
UY (1) UY34315A (pt)
WO (2) WO2013036563A1 (pt)
ZA (1) ZA201401040B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE031435T2 (en) * 2011-09-08 2017-07-28 Mereo Biopharma 2 Ltd Pharmaceutical compositions comprising an aromatase inhibitor
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
MX2016017315A (es) * 2014-07-07 2017-04-27 Novartis Ag Formas de dosificacion farmaceutica.
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (pt) * 1990-12-12 1993-08-01 Ciba Geigy Ag
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
AU2001271162A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
DK1381431T3 (da) * 2001-04-17 2007-10-08 Ares Trading Sa Aromatase-inhibition for at foröge implantationsrate
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US20040235812A1 (en) * 2002-04-03 2004-11-25 Caspers Robert F Pharmaceutical composition comprisng an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
EP1937251A2 (en) * 2005-04-25 2008-07-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335219A (zh) * 2007-11-21 2012-02-01 客乐谐制药株式会社 芳香酶抑制剂
HUE031435T2 (en) * 2011-09-08 2017-07-28 Mereo Biopharma 2 Ltd Pharmaceutical compositions comprising an aromatase inhibitor

Also Published As

Publication number Publication date
AU2012304693A1 (en) 2014-03-13
US9370505B2 (en) 2016-06-21
ES2613666T3 (es) 2017-05-25
AU2012304694A1 (en) 2014-03-20
IL231234A0 (en) 2014-04-30
PL2753313T3 (pl) 2017-07-31
CN103796644B (zh) 2017-05-03
CY1118499T1 (el) 2017-07-12
JP6051467B2 (ja) 2016-12-27
AU2012304693B2 (en) 2016-03-31
MX343902B (es) 2016-11-28
PE20141584A1 (es) 2014-11-13
RU2617510C2 (ru) 2017-04-25
DK2753312T3 (da) 2017-02-13
IL231234A (en) 2016-12-29
EP2753312A1 (en) 2014-07-16
ZA201401040B (en) 2015-12-23
HUE031435T2 (en) 2017-07-28
BR112014005434A2 (pt) 2017-04-04
EP2753313B1 (en) 2016-12-14
CA2846884A1 (en) 2013-03-14
BR112014005434B1 (pt) 2021-01-05
TW201316987A (zh) 2013-05-01
JP6280501B2 (ja) 2018-02-14
MX2014002780A (es) 2014-06-05
SI2753313T1 (sl) 2017-04-26
BR112014004879B1 (pt) 2020-01-28
KR20180030254A (ko) 2018-03-21
CA2846884C (en) 2019-04-09
IN2014DN01619A (pt) 2015-05-15
SG2014012132A (en) 2014-06-27
EP2753313A1 (en) 2014-07-16
US20140213622A1 (en) 2014-07-31
CY1118461T1 (el) 2017-07-12
KR20140071358A (ko) 2014-06-11
CL2014000552A1 (es) 2014-09-12
PT2753313T (pt) 2017-02-02
US20140309267A1 (en) 2014-10-16
HUE031478T2 (hu) 2017-07-28
US20160346257A1 (en) 2016-12-01
DK2753313T3 (en) 2017-02-13
US10064844B2 (en) 2018-09-04
CA2845929A1 (en) 2013-03-14
RU2014113334A (ru) 2015-10-20
SI2753312T1 (sl) 2017-10-30
SG10201607503WA (en) 2016-10-28
KR20140058619A (ko) 2014-05-14
KR101872561B1 (ko) 2018-06-28
CA2845929C (en) 2018-06-19
AU2012304694B2 (en) 2016-04-07
CN103781476B (zh) 2016-12-07
PT2753312T (pt) 2017-02-03
RU2628808C2 (ru) 2017-08-22
EP2753312B1 (en) 2016-12-14
JP2014528932A (ja) 2014-10-30
NZ621476A (en) 2016-02-26
LT2753313T (lt) 2017-02-10
JP2014526465A (ja) 2014-10-06
CN103796644A (zh) 2014-05-14
AR087790A1 (es) 2014-04-16
RU2014113575A (ru) 2015-10-20
CN103781476A (zh) 2014-05-07
HRP20170003T1 (hr) 2017-03-10
US20160243084A1 (en) 2016-08-25
UY34315A (es) 2013-04-30
MX360315B (es) 2018-10-29
WO2013036563A1 (en) 2013-03-14
HRP20170002T1 (hr) 2017-02-24
WO2013036562A1 (en) 2013-03-14
LT2753312T (lt) 2017-01-25
US9295668B2 (en) 2016-03-29
PL2753312T3 (pl) 2017-06-30
MX2014002773A (es) 2014-06-05
TN2014000059A1 (en) 2015-07-01
US9750724B2 (en) 2017-09-05
ES2613667T3 (es) 2017-05-25

Similar Documents

Publication Publication Date Title
BR112014004879A2 (pt) uso de inibidor de aromatase para tratamento de hipogonadismo e doenças relacionadas
DOP2013000252A (es) FORMULACION PARA ANTICUERPO ANTI-a4ß7
MX369385B (es) Productos para cicatrizar heridas tisulares.
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
WO2014022739A3 (en) Modified rnai agents
MX2015008697A (es) Tratamiento contra la degeneración macular relacionada con la edad.
MX360391B (es) Composiciones liposomales combinadas para terapia contra el cancer.
MX343534B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
UY34896A (es) Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
BR112015019524A2 (pt) tratamento de combinação
MX362485B (es) Nuevos inhibidores de rock.
DOP2013000004A (es) Agentes terapeuticos 976
ECSP12012332A (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
MX359171B (es) Tratamiento para diabetes tipo i y tipo ii.
EA201491769A1 (ru) Фармацевтическая композиция с фиксированной дозой, содержащая мометазон и азеластин
CO6630144A2 (es) Asociación de inhibidores de la xantina oxidasa y la instatina y su uso
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
CL2010001230A1 (es) Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2012, OBSERVADAS AS CONDICOES LEGAIS.